Medivation — Q1 2016 Earnings Presentation
17 slides from Medivation's earnings presentation, May 6, 2016
Slide 1: Financial and Corporate Update
Financial and Corporate Update Exhibit 99.1
Slide 2: Speakers
Speakers David Hung, M.D. – Founder, President and CEO Marion McCourt – Chief Operating Officer Jennifer Jarrett – Chief Financial Officer Mohammad Hirmand, M.D. – Interim Chief Medical Officer
Slide 3: Additional Information: Forward-Looking Statements
Additional Information Forward-Looking Statements This presentation contains forward-looking statements. All statements relating to events or results that may occur in the future, including but not limited to statements regarding our future results of operations and financial position, our anticipat
Slide 4: David Hung, M.D. – Founder, President and CEO
David Hung, M.D. Founder, President and CEO
Slide 5: Marion McCourt – Chief Operating Officer
Marion McCourt Chief Operating Officer
Slide 6: Jennifer Jarrett – Chief Financial Officer
Jennifer Jarrett Chief Financial Officer
Slide 7: U.S. XTANDI Net Sales
Year over year increase in U.S. XTANDI net sales of 37% was driven by an increase in underlying demand of 33% Sequential quarter decrease in U.S. XTANDI net sales in Q1 2016 was due to higher gross-to-net (due to reset of Medicare Part D “donut hole”) and a decrease in inventory at channel partners
Slide 8: Ex-U.S. XTANDI Net Sales
+80% increase y-o-y Ex-U.S. XTANDI Net Sales As recorded by Astellas Ex-US XTANDI net sales were approximately $240 million in Q1 2016, an increase of 80% compared to Q1 2015 The increase was primarily driven by growth in Germany, France and Japan Key Metrics & Comments
Slide 9: Medivation Non-GAAP Revenue
Medivation Non-GAAP Revenue Non-GAAP revenues typically lower in first quarter of calendar year due to: Reset of royalty rate on ex-U.S. net sales of XTANDI effective January 1st of each calendar year The seasonal effects that were detailed on the previous slide, notable a higher gross to net accrua
Slide 10: Non-GAAP R&D Expenses
Non-GAAP R&D Expenses Year over year increase in Non-GAAP R&D, primarily related to our talazoparib program which we acquired in October 2015 Modest 11% quarter over quarter growth and this sequential growth rate is expected to decline in subsequent quarters Key Metrics & Comments Acquired Talazopar
Slide 11: Non-GAAP SG&A Expenses
Non-GAAP SG&A Expenses First quarter Non-GAAP SG&A expenses were impacted by annually recurring collaboration expenses incurred by Astellas that are expensed to us almost entirely in the first quarter of the year Consistent with last year, we expect our Non-GAAP SG&A expense to decrease in subsequen
Slide 12: Non-GAAP EPS
Non-GAAP EPS First quarter EPS generally lower due to: Lower Non-GAAP revenues due to 1) reset of royalty rate on XTANDI ex-U.S. net sales and 2) higher gross to net and inventory changes related to US net sales of XTANDI Higher Non-GAAP S&GA expenses due to timing of certain collaboration expenses
Slide 13: Reaffirming Full Year 2016 Non-GAAP Guidance
Reaffirming Full Year 2016 Non-GAAP Guidance All amounts in $ millions except for Tax Rate and EPS 2016 FY Guidance US XTANDI Sales (1) $1,425 - $1,525 Non-GAAP Collaboration Revenue (2) $900 - $970 Non-GAAP Operating Expenses (3) $555 - $600 Non-GAAP R&D Expenses $280 - $300 Non-GAAP SG&A Expenses
Slide 14: Non-GAAP Financial Measures
Non-GAAP Financial Measures
Slide 15: Reconciliation of GAAP Reported to Non-GAAP (1 of 2)
Reconciliation of GAAP Reported to Non-GAAP (1 of 2)
Slide 16: Reconciliation of GAAP Reported to Non-GAAP (2 of 2)
Reconciliation of GAAP Reported to Non-GAAP (2 of 2)
Slide 17: Explanation of Adjustments to Reconciliation Tables
Explanation of Adjustments to Reconciliation Tables a) Upfront and milestone payments from Astellas: Upfront and milestone payments are excluded from non-GAAP financial measures because they occur at irregular intervals and are not related to Medivation’s long term core business going forward; such